- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06389474
Efficacy of INM004 in Children With STEC-HUS
A Phase III Study to Evaluate the Efficacy of INM004 (Shiga Antitoxin) in Pediatric Patients With Shiga Toxin-producing Escherichia Coli-associated Hemolytic Uremic Syndrome.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary objective will be to evaluate the efficacy of INM004, added to the standard of care, as a treatment for STEC-HUS in the amelioration of renal function.
Secondary objectives
- To evaluate the efficacy of INM004 in the reduction of mortality.
- To evaluate the efficacy of INM004 in the prevention and reduction of extrarenal complications.
- To evaluate the efficacy of INM004 in the improvement of TMA laboratory parameters.
- To evaluate the efficacy of INM004 in the reduction of hospital stay days.
- To evaluate the safety of INM004
- To evaluate the pharmacokinetics of INM004
- To evaluate the kinetics of Stx
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Santiago Sanguineti, Ph.D
- Phone Number: 6184 +541120331455
- Email: ssanguineti@inmunova.com
Study Contact Backup
- Name: Mariana Colonna, Bioch
- Email: mcolonna@inmunova.com
Study Locations
-
-
-
Ciudad Autonoma de Buenos Aire, Argentina
- Hospital de Niños Dr. Ricardo Gutierrez
-
Ciudad Autonoma de Buenos Aire, Argentina
- Clínica Zabala
-
Córdoba, Argentina
- Sanatorio Allende
-
Córdoba, Argentina
- Hospital de Niños de la Santísima Trinidad
-
Mendoza, Argentina
- Hospital Pediátrico Dr. Humberto Notti
-
-
Buenos Aires
-
Florencio Varela, Buenos Aires, Argentina
- Hospital El Cruce - Néstor Kirchner
-
Mar Del Plata, Buenos Aires, Argentina
- Hospital Interzonal Especializado Materno Infantil Don Victorio Tetamanti
-
-
Santa Fe
-
Rosario, Santa Fe, Argentina
- Sanatorio de Niños
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 9 months and < 18 years at the time of randomization.
In addition, only for subjects < 1 year and ≥ 15 years, confirmation of STEC infection determined by:
- Detection of generic Stx, Stx1, Stx2, or Stx1/Stx2 in stools by enzyme immunoassay (EIA); or
- Detection of stx, stx1, stx2, or stx1/stx2 genes in stools by Polymerase Chain Reaction (PCR); or
- Detection of specific anti-polysaccharide (IgM) antibodies in serum; or
- Fecal culture positive for E. coli O157 confirmed by serogroup-specific seroagglutination.
- Hospitalization at the participating institution.
- History of onset of diarrhea within 10 days prior to STEC-HUS diagnosis at the participating institution.
Diagnosis of STEC-HUS defined as a subject with signs of renal damage, hemolysis, and platelet consumption:
Signs of renal damage defined as:
- Serum creatinine value above the ULN for age and sex, and GFR below the LLN for age, sex, and height.
Presence of hemolysis documented by:
- LDH levels above the ULN for age, and/or
- Presence of schistocytes in peripheral blood smear.
Platelet consumption according to any of the following laboratory criteria:
- Peripheral blood platelet count < 150 × 103/μL, and/or
- A ≥50% decrease in peripheral blood platelet count compared to a sample collected within the previous 24 hours.
- Informed consent form signed and dated by the subject or, the legal guardian(s), with the subject's assent as appropriate based on age and regulatory guidelines in the region.
- Subjects who have already had menarche must have a negative pregnancy test.
Exclusion Criteria:
- Start of dialysis within 48 hours prior to admission to the participating institution.
- More than 24 hours from diagnosis of STEC-HUS at the participating institution up to randomization.
- History of chronic/recurrent hemolytic anemia, thrombocytopenia, or CKD.
- Personal and/or family history of atypical HUS.
- Suspected HUS secondary to infectious processes other than gastrointestinal (e.g., Streptococcus pneumoniae, HIV).
- Suspected HUS secondary to other etiologies (e.g., drug-associated HUS, neoplasms, bone marrow or solid organ transplantation, autoimmune disorders).
- Any other acute or chronic medical condition that, in the opinion of the investigator, may interfere with the evaluation of the efficacy and/or safety of the study medication.
- History of: a) anaphylaxis of any kind; b) prior administration of equine serum (e.g., antivenom, anti-arachnid serum, anti-SARS-CoV-2 serum, etc.) or an allergic reaction from contact or exposure to horses.
- Pregnant or breastfeeding woman.
- Impossibility of hospitalization in the participating institution.
- Concurrent participation in another clinical trial or having participated in a clinical trial in the last 3 months.
- Severe malnutrition. Defined when the weight is three standard deviations below the median, according to height, age and sex as per WHO guidelines.
Medical conditions that may affect kidney function or cause/enhance neurological symptoms or signs:
- Congenital or acquired anomalies that may affect functioning renal mass.
- Epilepsy or structural abnormalities of the brain that may increase the risk of seizures.
- Trisomy 21.
- Prematurity (born before 28 weeks gestation).
- Other (according to investigator criteria).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: INM004
Two doses of Anti-Shiga Toxin Hyperimmune Equine Immunoglobulin F(ab´)2 fragment at a dosage of 4 mg/kg of body weight, 24 hours apart.
|
Two doses of Anti-Shiga Toxin Hyperimmune Equine Immunoglobulin F(ab´)2 fragments at a dosage of 4 mg/kg of body weight, 24 hours apart.
Each vial contains 25 mg of protein/ml.
Therefore, each subject must receive 0.16 ml/kg per dose.
The vial volume will be reconstituted in a 100 ml (for subjects with a body weight of 20 kg or more) or 50 ml (for subjects under 20 kg of body weight) infusion bag.
It will be administered as an intravenous infusion using an infusion pump over a period of 50 minutes.
In subjects with a BMI over 30 kg/m2, infusion will be performed over a period of 100 minutes
Other Names:
|
Placebo Comparator: Placebo
Two doses of saline solution, 24 hours apart.
|
Two doses of placebo, 24 hours apart.
The placebo solution has the same composition of excipients as INM004 without the active pharmaceutical ingredient, and its appearance is identical.
Each subject must receive 0.16 ml/kg of placebo solution per dose.
The vial volume will be reconstituted in a 100 ml (for subjects with a body weight of 20 kg or more) or 50 ml (for subjects under 20 kg of body weight) infusion bag.
It will be administered as an intravenous infusion using an infusion pump over a period of 50 minutes.
In subjects with a BMI over 30 kg/m2, infusion will be performed over a period of 100 minutes
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to recovery of renal function during the acute phase
Time Frame: 28 days
|
Time (days) to achieve a glomerular filtration rate greater than or equal to the lower limit of normal (according to age, height, and sex) and a serum creatinine lower than or equal to the upper limit of normal (according to age and sex), both measured in the absence of dialysis.
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Short-term recovery of renal function
Time Frame: 90 days
|
Proportion of subjects with a glomerular filtration rate ≥ lower limit of normal (according to age, height and sex) and serum creatinine ≤ upper limit of normal (according to age and sex), both measured in the absence of dialysis.
|
90 days
|
MAKE 90
Time Frame: 90 days
|
Proportion of subjects meeting any of the following criteria at day 90: death, dialysis requirement after 24 hours post-randomization, dialysis of more than 10 days, or persistent decline in renal function (without recovery of glomerular filtration rate according to age, height, and sex).
|
90 days
|
Dialysis longer than 10 days
Time Frame: 90 days
|
Proportion of dialyzed subjects requiring more than 10 days of dialysis
|
90 days
|
Dialysis requirement
Time Frame: 90 days
|
Proportion of subjects requiring dialysis after 24 hours post-randomization
|
90 days
|
Mortality
Time Frame: 90 days
|
Proportion of subjects who die from any cause.
|
90 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events
Time Frame: 90 days
|
Incidence of adverse events
|
90 days
|
CKD Risk Assessment According to Kidney Disease Improving Global Outcomes (KDIGO) Categories
Time Frame: 90 days
|
Proportion of subjects in each CKD category (low, medium, high, very high) according to GFR and albuminuria at day 90
|
90 days
|
Evolution of renal function at 7 days (GFR_AUC1-7)
Time Frame: 7 days
|
Area under the curve of glomerular filtration rate from Day 1 to Day 7
|
7 days
|
Evolution of renal function at 28 days (GFR_AUC1-28)
Time Frame: 28 days
|
Area under the curve of glomerular filtration rate from Day 1 to Day 28
|
28 days
|
Evolution of renal function at 90 days (GFR_AUC1-90)
Time Frame: 90 days
|
Area under the curve of glomerular filtration rate from Day 1 to Day 90
|
90 days
|
Incidence of anuria
Time Frame: 90 days
|
Proportion of subjects with anuria onset after 24 hours post-randomization
|
90 days
|
Extrarenal composite endpoint
Time Frame: 90 days
|
Proportion of subjects who develop at least one severe extrarenal event including neurological events (coma, seizure, stroke), cardiovascular (hemodynamic instability, heart failure, acute myocardial infarction, myocarditis), respiratory (respiratory distress), gastrointestinal (hemorrhagic colitis, intestinal necrosis, intussusception, pancreatitis, severe hepatitis) or death.
|
90 days
|
Recovery of the thrombotic microangiopathy (TMA), thrombocytopenia
Time Frame: 90 days
|
Normalization of thrombocytopenia (platelet count ≥150,000/mm3), measured as time to recovery.
|
90 days
|
Recovery of the thrombotic microangiopathy (TMA), hemolytic anemia
Time Frame: 90 days
|
Proportion of subjects with recovery from hemolytic anemia (Hemoglobin ≥ lower limit of normal and Lactate Dehydrogenase ≤ upper limit of normal).
|
90 days
|
Duration of hospitalization
Time Frame: 90 days
|
Time from randomization to hospital discharge.
|
90 days
|
Incidence of adverse events of special interest
Time Frame: 28 days
|
|
28 days
|
Pharmacokinetic - AUC0-t
Time Frame: 144 hours
|
Area under the curve of INM004 concentration from time 0 to the last measurable concentration
|
144 hours
|
Pharmacokinetic - AUC0-inf
Time Frame: 144 hours
|
Area under the curve of INM004 concentration as a function of time extrapolated to infinity
|
144 hours
|
Pharmacokinetic - Cmax
Time Frame: 144 hours
|
Maximum concentration of INM004 in plasma after administration
|
144 hours
|
Pharmacokinetic - Tmax
Time Frame: 144 hours
|
Time in which INM004 reaches the maximum concentration in plasma after administration
|
144 hours
|
Pharmacokinetic - λz
Time Frame: 144 hours
|
Terminal velocity constant via linear logit regression
|
144 hours
|
Pharmacokinetic - t1/2
Time Frame: 144 hours
|
Terminal half-life of INM004
|
144 hours
|
Pharmacokinetic - Vz
Time Frame: 144 hours
|
Volume of distribution of INM004
|
144 hours
|
Pharmacokinetic - Cl
Time Frame: 144 hours
|
INM004 clearence
|
144 hours
|
Pharmacokinetic - AUC/dose
Time Frame: 144 hours
|
Area under the curve of INM004 normalized for the administered dose
|
144 hours
|
Pharmacokinetic - Cmax/dose
Time Frame: 144 hours
|
Maximum concentration of INM004 in plasma normalized for the administered dose
|
144 hours
|
Baseline Shiga toxin serum levels
Time Frame: Baseline
|
Baseline serum Stx2 concentration in all subjects
|
Baseline
|
Kinetics of Shiga toxin in serum
Time Frame: 144 hours
|
Serum Stx2 concentration at different time-points in placebo subjects.
|
144 hours
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Santiago Sanguineti, Ph.D, Inmunova S.A.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Kidney Diseases
- Urologic Diseases
- Disease
- Hematologic Diseases
- Anemia
- Thrombocytopenia
- Blood Platelet Disorders
- Anemia, Hemolytic
- Thrombotic Microangiopathies
- Uremia
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Cytopenia
- Syndrome
- Azotemia
- Hemolysis
- Hemolytic-Uremic Syndrome
Other Study ID Numbers
- CT-INM004-04
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemolytic-Uremic Syndrome
-
AlexionCompletedAtypical Hemolytic-Uremic SyndromeUnited Kingdom, United States, France, Italy, Germany, Spain, Belgium
-
Alexion PharmaceuticalsCompletedAtypical Hemolytic-Uremic SyndromeUnited Kingdom, Belgium, United States, Germany, Italy, France, Netherlands, Australia, Canada
-
AlexionSyneos HealthRecruitingAtypical Hemolytic-Uremic SyndromeFrance, Germany, Israel, Italy, United Kingdom, Canada, United States, Australia, Belgium, Denmark, Korea, Republic of, Poland, Russian Federation, Spain, Taiwan
-
Alexion PharmaceuticalsCompletedAtypical Hemolytic Uremic Syndrome (aHUS)Japan
-
Alexion PharmaceuticalsCompletedATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)Japan
-
University Hospital, ToursHospices Civils de Lyon; University Hospital, Strasbourg, France; University... and other collaboratorsActive, not recruitingHemolytic-Uremic Syndrome, AtypicalFrance
-
Maastricht University Medical CenterRecruitingThrombotic Microangiopathies | Hemolytic-Uremic Syndrome | Hemolytic Uremic Syndrome, AtypicalNetherlands
-
Omeros CorporationUnknownThrombotic Microangiopathies | Atypical Hemolytic Uremic SyndromeUnited States
-
Mario Negri Institute for Pharmacological ResearchChemoCentryxTerminated
-
AstraZenecaRecruitingAtypical Hemolytic Uremic Syndrome(aHUS)China
Clinical Trials on INM004
-
Inmunova S.A.Hospital Italiano de Buenos AiresCompletedHealthy VolunteersArgentina
-
Inmunova S.A.ExeltisTerminatedHemolytic-Uremic Syndrome | Pediatric Kidney Disease | Bloody Diarrhea | STEC, UnspecifiedArgentina
-
Inmunova S.A.Linical Co., Ltd.; KLIXAR; PHV LATAMCompletedHemolytic-Uremic Syndrome | Pediatric Kidney Disease | Diarrhea-Associated Hemolytic Uremic SyndromeArgentina